+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Psoriatic Arthritis Treatment Market by Drug Type, Type, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5021812
  • Report
  • January 2020
  • Region: Global
  • 228 pages
  • Allied Analytics LLP

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • Celgene Corporation
  • Eli Lilly And Company
  • Johnson & Johnson
  • Merck & Co Inc.
  • MORE
The psoriatic arthritis treatment market was valued at $7,860 million in 2018, and is estimated to reach at $13,744 million by 2026, registering a CAGR of 7.2% from 2019 to 2026. Psoriatic arthritis is an autoimmune disease caused by an attack of body’s immune system on skin and joint. The disease is characterized by stiffness, swelling in the joints, and pain. Symmetric psoriatic arthritis, asymmetric psoriatic arthritis, spondylitis, distal psoriatic arthritis, and arthritis mutilans are the different types of psoriatic arthritis. Symptoms associated with this disorder include low back pain, conjunctivitis, swollen joint, nail pitting, and foot pain. The disorder is more prevalent among patients already suffering from psoriasis. Psoriatic arthritis can be diagnosed with tests such as rheumatoid factor (RF), joint fluid test, X-ray, and magnetic resonance imaging (MRI). Drugs used to treat psoriatic arthritis disease include NSAIDs, disease-modifying antirheumatic drugs (DMARDs), biologics, immunosuppressant drugs, and others.

Significant increase in prevalence of psoriatic arthritis, rise in demand for psoriatic arthritis pharmacotherapy, strong pipeline of biosimilar & biologic products, stressful lifestyle resulting in the overstimulation of immune system, and rise in geriatric population are the key factors that fuel the growth of the global psoriatic arthritis treatment market. Moreover, rise in adoption of psoriatic arthritis treatment medications, increase in R&D activities to develop new products for effective treatment of psoriatic arthritis, frequent product launches by key players, surge in awareness toward availability of treatment for psoriatic arthritis, and an increase in risk of diseases are other factors that contribute toward the growth of the market. However, lack of standardization tools for diagnosis and high cost of treatment are expected to hamper the market growth.

The global psoriatic arthritis treatment market is segmented into drug type, type, route of administration, and region. By drug type, the market is categorized into NSAIDs, DMARDs, biologics, and others. On the basis of type, the market is divided into prescription, and OTC. According to route of administration, it is segregated into topical, oral, and injectable. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Drug Type
  • NSAIDs
  • DMARDs
  • Biologics
  • Others
By Type
  • Prescription
  • OTC
By Route of Administration
  • Topical
  • Oral
  • Injectable
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly And Company
  • Johnson & Johnson
  • Merck & Co Inc.
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • F. Hoffmann-La Roche AG
  • Valeant Pharmaceuticals International, Inc.
  • Abbott Laboratories
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • Celgene Corporation
  • Eli Lilly And Company
  • Johnson & Johnson
  • Merck & Co Inc.
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter's Five Force Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rise In Prevalence of Psoriasis & Psoriatic Arthritis Disease
3.4.1.2. Increase In Number of Pipeline Drugs
3.4.1.3. Increase In Government Expenditure On Healthcare
3.4.2. Restraint
3.4.2.1. Poor Demand In Under Developed Countries
3.4.3. Opportunities
3.4.3.1. Growth Opportunities In Emerging Markets
3.4.4. Impact Analysis

Chapter 4: Psoriatic Arthritis Treatment Market, By Drug Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Nsaids
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Dmards
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
4.4. Biologics
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Analysis, By Country
4.5. Others
4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Analysis, By Country

Chapter 5: Psoriatic Arthritis Treatment Market, By Type
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Prescription
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.3. Otc
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country

Chapter 6: Psoriatic Arthritis Treatment Market, By Route of Administration
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Injectable
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Analysis, By Country
6.3. Oral
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country
6.4. Topical
6.4.1. Market Size And Forecast, By Region
6.4.2. Market Analysis, By Country

Chapter 7: Psoriatic Arthritis Treatment Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.2.1. U.S.
7.2.2.1.1. U.S. Psoriatic Arthritis Treatment Market, By Drug Type
7.2.2.1.2. U.S. Psoriatic Arthritis Treatment Market, By Type
7.2.2.1.3. U.S. Psoriatic Arthritis Treatment Market, By Route of Administration
7.2.2.2. Canada
7.2.2.2.1. Canada Psoriatic Arthritis Treatment Market, By Drug Type
7.2.2.2.2. Canada Psoriatic Arthritis Treatment Market, By Type
7.2.2.2.3. Canada Psoriatic Arthritis Treatment Market, By Route of Administration
7.2.2.3. Mexico
7.2.2.3.1. Mexico Psoriatic Arthritis Treatment Market, By Drug Type
7.2.2.3.2. Mexico Psoriatic Arthritis Treatment Market, By Type
7.2.2.3.3. Mexico Psoriatic Arthritis Treatment Market, By Route of Administration
7.2.3. North America Market Size And Forecast, By Drug Type
7.2.4. North America Market Size And Forecast, By Type
7.2.5. North America Market Size And Forecast, By Route of Administration
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.2.1. Germany
7.3.2.1.1. Germany Psoriatic Arthritis Treatment Market, By Drug Type
7.3.2.1.2. Germany Psoriatic Arthritis Treatment Market, By Type
7.3.2.1.3. Germany Psoriatic Arthritis Treatment Market, By Route of Administration7.3.2.2. France
7.3.2.2.1. France Psoriatic Arthritis Treatment Market, By Drug Type
7.3.2.2.2. France Psoriatic Arthritis Treatment Market, By Type
7.3.2.2.3. France Psoriatic Arthritis Treatment Market, By Route of Administration
7.3.2.3. UK
7.3.2.3.1. UK Psoriatic Arthritis Treatment Market, By Drug Type
7.3.2.3.2. UK Psoriatic Arthritis Treatment Market, By Type
7.3.2.3.3. UK Psoriatic Arthritis Treatment Market, By Route of Administration
7.3.2.4. Italy
7.3.2.4.1. Italy Psoriatic Arthritis Treatment Market, By Drug Type
7.3.2.4.2. Italy Psoriatic Arthritis Treatment Market, By Type
7.3.2.4.3. Italy Psoriatic Arthritis Treatment Market, By Route of Administration
7.3.2.5. Spain
7.3.2.5.1. Spain Psoriatic Arthritis Treatment Market, By Drug Type
7.3.2.5.2. Spain Psoriatic Arthritis Treatment Market, By Type
7.3.2.5.3. Spain Psoriatic Arthritis Treatment Market, By Route of Administration
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Psoriatic Arthritis Treatment Market, By Drug Type
7.3.2.6.2. Rest of Europe Psoriatic Arthritis Treatment Market, By Type
7.3.2.6.3. Rest of Europe Psoriatic Arthritis Treatment Market, By Route of Administration
7.3.3. Europe Market Size And Forecast, By Drug Type
7.3.4. Europe Market Size And Forecast, By Type
7.3.5. Europe Market Size And Forecast, By Route of Administration
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.2.1. Japan
7.4.2.1.1. Japan Psoriatic Arthritis Treatment Market, By Drug Type
7.4.2.1.2. Japan Psoriatic Arthritis Treatment Market, By Type
7.4.2.1.3. Japan Psoriatic Arthritis Treatment Market, By Route of Administration
7.4.2.2. China
7.4.2.2.1. China Psoriatic Arthritis Treatment Market, By Drug Type
7.4.2.2.2. China Psoriatic Arthritis Treatment Market, By Type
7.4.2.2.3. China Psoriatic Arthritis Treatment Market, By Route of Administration
7.4.2.3. Australia
7.4.2.3.1. Australia Psoriatic Arthritis Treatment Market, By Drug Type
7.4.2.3.2. Australia Psoriatic Arthritis Treatment Market, By Type
7.4.2.3.3. Australia Psoriatic Arthritis Treatment Market, By Route of Administration
7.4.2.4. India
7.4.2.4.1. India Psoriatic Arthritis Treatment Market, By Drug Type
7.4.2.4.2. India Psoriatic Arthritis Treatment Market, By Type
7.4.2.4.3. India Psoriatic Arthritis Treatment Market, By Route of Administration
7.4.2.5. South Korea
7.4.2.5.1. South Korea Psoriatic Arthritis Treatment Market, By Drug Type
7.4.2.5.2. South Korea Psoriatic Arthritis Treatment Market, By Type
7.4.2.5.3. South Korea Psoriatic Arthritis Treatment Market, By Route of Administration
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type
7.4.2.6.2. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Type
7.4.2.6.3. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration
7.4.3. Asia-Pacific Market Size And Forecast, By Drug Type
7.4.4. Asia-Pacific Market Size And Forecast, By Type
7.4.5. Asia-Pacific Market Size And Forecast, By Route of Administration
7.5. LAMEA
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.2.1. Brazil
7.5.2.1.1. Brazil Psoriatic Arthritis Treatment Market, By Drug Type
7.5.2.1.2. Brazil Psoriatic Arthritis Treatment Market, By Type
7.5.2.1.3. Brazil Psoriatic Arthritis Treatment Market, By Route of Administration
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia Psoriatic Arthritis Treatment Market, By Drug Type
7.5.2.2.2. Saudi Arabia Psoriatic Arthritis Treatment Market, By Type
7.5.2.2.3. Saudi Arabia Psoriatic Arthritis Treatment Market, By Route of Administration
7.5.2.3. South Africa
7.5.2.3.1. South Africa Psoriatic Arthritis Treatment Market, By Drug Type
7.5.2.3.2. South Africa Psoriatic Arthritis Treatment Market, By Type
7.5.2.3.3. South Africa Psoriatic Arthritis Treatment Market, By Route of Administration
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA Psoriatic Arthritis Treatment Market, By Drug Type
7.5.2.4.2. Rest of LAMEA Psoriatic Arthritis Treatment Market, By Type
7.5.2.4.3. Rest of LAMEA Psoriatic Arthritis Treatment Market, By Route of Administration
7.5.3. LAMEA Market Size And Forecast, By Drug Type
7.5.4. LAMEA Market Size And Forecast, By Type
7.5.5. LAMEA Market Size And Forecast, By Route of Administration

Chapter 8: Company Profiles
8.1. Abbvie Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves And Developments
8.2. Amgen Inc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves And Developments
8.3. Bristol-Myers Squibb Company
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves And Developments
8.4. Eli Lilly And Company.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves And Developments
8.5. Johnson & Johnson.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments
8.6. Merck & Co Inc.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Mylan N.V
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Novartis Ag
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. Pfizer Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Ucb S.A.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • Celgene Corporation
  • Eli Lilly And Company
  • Johnson & Johnson
  • Merck & Co Inc.
  • MORE
According to the report, titled, 'Psoriatic Arthritis Treatment Market by Drug Type, Type, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global psoriatic arthritis treatment market size was valued at $7,860 million in 2018, and is projected to reach $13,744 million by 2026, growing at a CAGR of 7.2% from 2019 to 2026.

Psoriatic arthritis is a form of arthritis disorder developed in individuals affected by psoriasis. It leads to joint stiffness, pain, and swelling. Most individuals initially develop psoriasis and are later diagnosed with psoriatic arthritis. According to a study published by Celgene Corporation, in 2018, approximately 30% of patients with psoriasis disorder develop inflammatory situation involving joints, known as psoriatic arthritis. Several prescription and over-the-counter (OTC) drugs are available for the treatment of psoriatic arthritis. Some treat symptoms of both psoriatic arthritis and psoriasis, while others help with joint issues. Medications for psoriatic arthritis treatment include NSAIDs, DMARDs, biologics, and others.

The major factors that boost the growth of the global psoriatic arthritis treatment market are rise in prevalence of psoriatic arthritis, surge in geriatric population, strong pipeline of biosimilar & biologic products, increase in demand for psoriatic arthritis drugs, and upsurge in awareness toward availability of treatment for psoriatic arthritis. In addition, strong efficacy of approved drugs, presence of large patient pool, the increase in the adoption of novel treatments, and surge in clinical R&D to develop new drugs for the treatment of psoriatic arthritis are expected to boost the market growth during the forecast period. Furthermore, increased risk of diseases and rise in healthcare expenditure are expected to offer lucrative opportunities for market expansion during the forecast period. However, high cost of treatment and lack of standardization tools for diagnosis are expected to hamper the psoriatic arthritis treatment market growth.

On the basis of drug type, the market is categorized into NSAIDs, DMARDs, biologics, and others. Presently, the biologics segment dominates the global market, and is anticipated to continue this trend during the forecast period. This is attributed to rise in adoption of biological therapies, increase in demand & higher acceptability for innovative therapies, and availability of generic biologic. Moreover, rise in incidence of psoriatic arthritis, increase in biologics in pipeline, and advancements in biologics coupled with minimal side effects have boosted the growth of the biologics segment.

According to route of administration, the psoriatic arthritis treatment market is fragmented into topical, oral, and injectable. Presently, the oral segment is the major shareholder in the global psoriatic arthritis treatment market, owing to rise in demand for oral psoriatic arthritis treatment drugs, increase in awareness toward availability of psoriatic arthritis treatment, surge in R&D activities to develop new drugs, rise in consumption of oral psoriatic arthritis treatment drugs, and low cost of oral NSAIDs drugs. In addition, rise in healthcare budgets of developed & developing countries is expected to offer remunerative opportunities for psoriatic arthritis treatment market expansion in the near future.

Key Findings of the Study
On the basis of drug type, the biologics segment held more than one-half share in the global market in 2018.
By type, the prescription drug segment accounted for the largest market share in 2018, and is expected to remain dominant throughout the forecast period.
Depending on route of administration, the injectable segment held more than half share in the global market in 2018.
Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.1% during the forecast period.
In 2018, North America accounted for the major share in the psoriatic arthritis treatment market, and is expected to continue this psoriatic arthritis treatment market trend during the forecast period, owing to availability of well-developed infrastructure, rise in R&D activities coupled with presence of key players, increase in demand for psoriatic arthritis treatment drugs, surge in production of biologics & generics, and an increase in nongovernment & government initiatives to promote healthcare. However, Asia-Pacific is expected to register the highest growth in the coming future, owing to improvement in healthcare infrastructure, technological advancements in the field of healthcare, and development of the R&D sector.
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly And Company
  • Johnson & Johnson
  • Merck & Co Inc.
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll